{"id":"gemcitabine-cisplatin-followed-by-docetaxel","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Neutropenia"},{"rate":"20-30%","effect":"Nausea and vomiting"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gemcitabine, cisplatin, and docetaxel work synergistically to induce apoptosis in cancer cells. Gemcitabine inhibits DNA synthesis, while cisplatin cross-links DNA, and docetaxel stabilizes microtubules, ultimately leading to cell death.","oneSentence":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, and docetaxel is a taxane that stabilizes microtubules.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:01:00.740Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT05281471","phase":"PHASE3","title":"Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)","status":"RECRUITING","sponsor":"Genelux Corporation","startDate":"2022-08-31","conditions":"Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer","enrollment":186},{"nctId":"NCT03178552","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2017-09-22","conditions":"Non-Small Cell Lung Cancer","enrollment":1000},{"nctId":"NCT06592599","phase":"PHASE2","title":"Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-09-03","conditions":"Nasopharyngeal Carcinoma","enrollment":24},{"nctId":"NCT02486718","phase":"PHASE3","title":"Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2015-10-31","conditions":"Non-Small Cell Lung Cancer","enrollment":1280},{"nctId":"NCT06623656","phase":"PHASE2","title":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-02-21","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":112},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT07088484","phase":"","title":"Watch-and-Wait After Immunochemotherapy in Locally Recurrent Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-08-01","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":50},{"nctId":"NCT06902272","phase":"PHASE2","title":"ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-06-11","conditions":"Non Small Cell Lung Cancer","enrollment":30},{"nctId":"NCT00446225","phase":"PHASE3","title":"Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2007-02-15","conditions":"Non-Small Cell Lung Cancer","enrollment":174},{"nctId":"NCT00324805","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-07-19","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7","enrollment":1501},{"nctId":"NCT00544414","phase":"PHASE2","title":"Chemotherapy Followed by Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Head And Neck Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2000-06-07","conditions":"Head and Neck Cancer","enrollment":31},{"nctId":"NCT03632798","phase":"PHASE3","title":"Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test in Recurrent Ovarian Cancer","status":"WITHDRAWN","sponsor":"Cordgenics, LLC","startDate":"2018-08-01","conditions":"Recurrent Ovarian Cancer","enrollment":""},{"nctId":"NCT02723955","phase":"PHASE1","title":"Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-23","conditions":"Neoplasms","enrollment":829},{"nctId":"NCT00478699","phase":"PHASE3","title":"Randomized Customized Adjuvant Chemotherapy (GECP-SCAT)","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2007-06","conditions":"Non-small-cell Lung Cancer","enrollment":500},{"nctId":"NCT02009449","phase":"PHASE1","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-11-15","conditions":"Melanoma, Prostate Cancer, Ovarian Cancer","enrollment":353},{"nctId":"NCT05517135","phase":"","title":"tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella)","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2022-11-17","conditions":"Nasopharyngeal Carcinoma","enrollment":1000},{"nctId":"NCT03949283","phase":"PHASE3","title":"Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cordgenics, LLC","startDate":"2019-07-26","conditions":"Recurrent Ovarian Carcinoma, Platinum-resistant Ovarian Cancer","enrollment":150},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT05583188","phase":"PHASE4","title":"Neoadjuvant Aliya™ PEF Soft Tissue Ablation With Systemic Therapy in Early-Stage Resectable NSCLC","status":"TERMINATED","sponsor":"Galvanize Therapeutics, Inc.","startDate":"2023-02-01","conditions":"NSCLC","enrollment":5},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT06156878","phase":"PHASE2","title":"PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-08-01","conditions":"Nasopharyngeal Carcinoma","enrollment":41},{"nctId":"NCT03840915","phase":"PHASE1, PHASE2","title":"M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-04-02","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":70},{"nctId":"NCT05116891","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cantargia AB","startDate":"2021-09-22","conditions":"Advanced Solid Tumors, Colorectal Cancer, Non Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT05834413","phase":"NA","title":"Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors","status":"NOT_YET_RECRUITING","sponsor":"Shanghai University of Traditional Chinese Medicine","startDate":"2023-05-01","conditions":"Lung Cancer","enrollment":367},{"nctId":"NCT02393248","phase":"PHASE1, PHASE2","title":"Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)","status":"TERMINATED","sponsor":"Incyte Corporation","startDate":"2015-02-27","conditions":"Lung Cancer, Solid Tumor, Gastric Cancer","enrollment":201},{"nctId":"NCT00312728","phase":"PHASE2","title":"A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2006-03","conditions":"Non-Small Cell Lung Cancer, Brain Neoplasms","enrollment":115},{"nctId":"NCT05622474","phase":"NA","title":"A Multicenter Randomized Controlled Clinical Study on the Treatment of T3N1M0 High Risk Nasopharyngeal Carcinoma With or Without Induction Chemotherapy Before Concurrent Radiotherapy and Chemotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2022-11-30","conditions":"Nasopharyngeal Carcinoma","enrollment":236},{"nctId":"NCT05320874","phase":"PHASE1","title":"A Study of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors.","status":"NOT_YET_RECRUITING","sponsor":"Xuanzhu Biopharmaceutical Co., Ltd.","startDate":"2022-04","conditions":"Advanced Solid Tumor","enrollment":232},{"nctId":"NCT04846634","phase":"PHASE2","title":"Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-08","conditions":"Resectable Locally Advanced Non-small Cell Lung Cancer","enrollment":90},{"nctId":"NCT03986463","phase":"","title":"CIrculating Tumour DNA in Lung Cancer (CITaDeL): Optimizing Sensitivity and Clinical Utility","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-01","conditions":"Lung Neoplasms, Lung Cancer, Neoplasm of Lung","enrollment":40},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02145078","phase":"NA","title":"Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer","status":"TERMINATED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2014-06","conditions":"Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":4},{"nctId":"NCT01443078","phase":"PHASE2","title":"Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-10","conditions":"Lung Cancer","enrollment":42},{"nctId":"NCT03604965","phase":"PHASE3","title":"GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC","status":"UNKNOWN","sponsor":"Guiyang Medical University","startDate":"2018-07-21","conditions":"Locally Advanced Nasopharyngeal Carcinoma","enrollment":204},{"nctId":"NCT03529279","phase":"PHASE3","title":"CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-06-12","conditions":"Nasopharyngeal Carcinoma","enrollment":1324},{"nctId":"NCT02455843","phase":"PHASE3","title":"Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC","status":"UNKNOWN","sponsor":"Shandong Provincial Hospital","startDate":"2015-05","conditions":"Non Small Cell Lung Cancer","enrollment":275},{"nctId":"NCT00705874","phase":"PHASE1","title":"Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma","status":"COMPLETED","sponsor":"Progen Pharmaceuticals","startDate":"2006-05","conditions":"Cancer","enrollment":172},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00509366","phase":"PHASE2","title":"Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Duke University","startDate":"2007-05","conditions":"Non Small Cell Lung Cancer","enrollment":101},{"nctId":"NCT00620971","phase":"PHASE2","title":"Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC","status":"COMPLETED","sponsor":"Hellenic Oncology Research Group","startDate":"2008-01","conditions":"Non Small Cell Lung Cancer","enrollment":77},{"nctId":"NCT00820755","phase":"PHASE3","title":"Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2009-01","conditions":"Non-Small Cell Lung Cancer (NSCLC)","enrollment":583},{"nctId":"NCT02016417","phase":"PHASE2","title":"Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Cancer Hospital of Guangxi Medical University","startDate":"2014-05","conditions":"Nasopharyngeal Carcinoma","enrollment":120},{"nctId":"NCT01596868","phase":"PHASE2","title":"GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest China","status":"COMPLETED","sponsor":"Air Force Military Medical University, China","startDate":"2012-05","conditions":"Nasopharyngeal Squamous Cell Carcinoma, Toxicity Due to Radiotherapy","enrollment":60},{"nctId":"NCT00173888","phase":"PHASE2","title":"Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2003-07","conditions":"Non-small Cell Lung Cancer","enrollment":15},{"nctId":"NCT00003587","phase":"PHASE2","title":"S9806: Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"1998-10","conditions":"Lung Cancer","enrollment":204},{"nctId":"NCT00454649","phase":"PHASE1","title":"Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-12","conditions":"Neoplasms","enrollment":102},{"nctId":"NCT00191139","phase":"PHASE2","title":"Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-03","conditions":"Non-small Cell Lung Cancer","enrollment":64},{"nctId":"NCT00425191","phase":"PHASE2","title":"Taxotere Combinations as First Line Therapy for Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-07","conditions":"Non-small Cell Lung Cancer","enrollment":165},{"nctId":"NCT00424853","phase":"PHASE2","title":"ADVANCED Phase II Trial of Weekly vs 3 Weekly Docetaxel and Cisplatin Followed by Gemcitabine in Non-small-cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-05","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":88},{"nctId":"NCT00270582","phase":"PHASE2","title":"A Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine vs. Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-Small-Cell Lung Cancer","status":"UNKNOWN","sponsor":"Far Eastern Memorial Hospital","startDate":"2005-11","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":58},{"nctId":"NCT00191490","phase":"PHASE2","title":"A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":162}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Gemcitabine cisplatin followed by docetaxel","genericName":"Gemcitabine cisplatin followed by docetaxel","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while cisplatin is a platinum-based alkylating agent that cross-links DNA, and docetaxel is a taxane that stabilizes microtubules. Used for Non-small cell lung cancer, Ovarian cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}